Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Want to cut your energy bills? Here’s how five experts are doing it 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
 - EconoTimes)
NEW ORLEANS, March 03, 2017 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until March 13, 2017 to file lead plaintiff applications in a securities class action lawsuit against Ophthotech Corporation (Nasdaq:OPHT), if they purchased the Company’s shares between May 11, 2015 and December 12, 2016, inclusive (the “Class Period”). The action is pending in United States District Court for the Southern District of New York.
What You May Do
If you purchased shares of Ophthotech and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 13, 2017.
About the Lawsuit
Ophthotech and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The complaint alleges that Ophthotech made overtly positive representations about the effectiveness and potential of its treatment Fovista when used in combination with Lucentis, a commercially available anti-vascular endothelial growth factor agent, despite awareness that the phase 3 clinical trial of Fovista would fail to achieve its primary endpoint.
On December 12, 2016, Ophthotech announced that the trial had failed to achieve its primary endpoint, and that Fovista and Lucentis demonstrated a non-statistically significant improvement over patients only receiving Lucentis.
On this news, the price of Ophthotech’s shares plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
